526 related articles for article (PubMed ID: 8623206)
1. CTLA4-Ig plus bone marrow induces long-term allograft survival and donor specific unresponsiveness in the murine model. Evidence for hematopoietic chimerism.
Pearson TC; Alexander DZ; Hendrix R; Elwood ET; Linsley PS; Winn KJ; Larsen CP
Transplantation; 1996 Apr; 61(7):997-1004. PubMed ID: 8623206
[TBL] [Abstract][Full Text] [Related]
2. Role of STAT4 and STAT6 signaling in allograft rejection and CTLA4-Ig-mediated tolerance.
Zhou P; Szot GL; Guo Z; Kim O; He G; Wang J; Grusby MJ; Newell KA; Thistlethwaite JR; Bluestone JA; Alegre ML
J Immunol; 2000 Nov; 165(10):5580-7. PubMed ID: 11067913
[TBL] [Abstract][Full Text] [Related]
3. Flt3-L augments the engraftment of donor-derived bone marrow cells when combined with sublethal irradiation and costimulatory (CD28/B7 and CD40/CD40L) blockade.
Woodward JE; Salam A; Logar AJ; Schaefer AT; Rao AS
Cell Transplant; 2002; 11(2):147-59. PubMed ID: 12099638
[TBL] [Abstract][Full Text] [Related]
4. Marked prolongation of cardiac allograft survival by dendritic cells genetically engineered with NF-kappa B oligodeoxyribonucleotide decoys and adenoviral vectors encoding CTLA4-Ig.
Bonham CA; Peng L; Liang X; Chen Z; Wang L; Ma L; Hackstein H; Robbins PD; Thomson AW; Fung JJ; Qian S; Lu L
J Immunol; 2002 Sep; 169(6):3382-91. PubMed ID: 12218160
[TBL] [Abstract][Full Text] [Related]
5. Use of CTLA4-Ig in combination with conventional immunosuppressive agents to prolong allograft survival.
Hale DA; Gottschalk R; Maki T; Monaco AP
Transplantation; 1997 Sep; 64(6):897-900. PubMed ID: 9326417
[TBL] [Abstract][Full Text] [Related]
6. Donor antigen is necessary for the prevention of chronic rejection in CTLA4Ig-treated murine cardiac allograft recipients.
Sayegh MH; Zheng XG; Magee C; Hancock WW; Turka LA
Transplantation; 1997 Dec; 64(12):1646-50. PubMed ID: 9422396
[TBL] [Abstract][Full Text] [Related]
7. Transplantation tolerance induced by CTLA4-Ig.
Pearson TC; Alexander DZ; Winn KJ; Linsley PS; Lowry RP; Larsen CP
Transplantation; 1994 Jun; 57(12):1701-6. PubMed ID: 8016872
[TBL] [Abstract][Full Text] [Related]
8. Protection of corneal allografts by CTLA4-Ig.
Gebhardt BM; Hodkin M; Varnell ED; Kaufman HE
Cornea; 1999 May; 18(3):314-20. PubMed ID: 10336035
[TBL] [Abstract][Full Text] [Related]
9. Aggressive skin allograft rejection in CD28-/- mice independent of the CD40/CD40L costimulatory pathway.
Ha J; Bingaman AW; Durham MM; Pearson TC; Larsen CP
Transpl Immunol; 2001 Oct; 9(1):13-7. PubMed ID: 11680567
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of corneal allograft reaction by CTLA4-Ig.
Hoffmann F; Zhang EP; Pohl T; Kunzendorf U; Wachtlin J; Bulfone-Paus S
Graefes Arch Clin Exp Ophthalmol; 1997 Aug; 235(8):535-40. PubMed ID: 9285225
[TBL] [Abstract][Full Text] [Related]
11. Blockade of the B7-CD28 pathway by CTLA4-Ig counteracts rejection and prolongs survival in small bowel transplantation.
Kurlberg G; Haglind E; Schön K; Törnqvist H; Lycke N
Scand J Immunol; 2000 Mar; 51(3):224-30. PubMed ID: 10736090
[TBL] [Abstract][Full Text] [Related]
12. CTLA4-Ig: a novel immunosuppressive agent.
Najafian N; Sayegh MH
Expert Opin Investig Drugs; 2000 Sep; 9(9):2147-57. PubMed ID: 11060799
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28.
Lin H; Rathmell JC; Gray GS; Thompson CB; Leiden JM; Alegre ML
J Exp Med; 1998 Jul; 188(1):199-204. PubMed ID: 9653096
[TBL] [Abstract][Full Text] [Related]
14. A clinically relevant CTLA4-Ig-based regimen induces chimerism and tolerance to heart grafts.
Li S; Thanikachalam M; Pang M; Kawaharada N; Aitouche A; Pham SM
Ann Thorac Surg; 2001 Oct; 72(4):1306-10. PubMed ID: 11603451
[TBL] [Abstract][Full Text] [Related]
15. Increased apoptosis of immunoreactive host cells and augmented donor leukocyte chimerism, not sustained inhibition of B7 molecule expression are associated with prolonged cardiac allograft survival in mice preconditioned with immature donor dendritic cells plus anti-CD40L mAb.
Lu L; Li W; Zhong C; Qian S; Fung JJ; Thomson AW; Starzl TE
Transplantation; 1999 Sep; 68(6):747-57. PubMed ID: 10515374
[TBL] [Abstract][Full Text] [Related]
16. Effect of administration of CTLA4-Ig as protein or cDNA on corneal allograft survival.
Comer RM; King WJ; Ardjomand N; Theoharis S; George AJ; Larkin DF
Invest Ophthalmol Vis Sci; 2002 Apr; 43(4):1095-103. PubMed ID: 11923251
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the B7 costimulatory pathway in allograft rejection.
Pearson TC; Alexander DZ; Corbascio M; Hendrix R; Ritchie SC; Linsley PS; Faherty D; Larsen CP
Transplantation; 1997 May; 63(10):1463-9. PubMed ID: 9175811
[TBL] [Abstract][Full Text] [Related]
18. Role of the CTLA4 pathway in hyporesponsiveness induced by intratracheal delivery of alloantigen.
Shirasugi N; Akiyama Y; Aramaki O; Shibutani S; Matsumoto K; Bashuda H; Yagita H; Okumura K; Ikeda Y; Niimi M
Transplantation; 2003 May; 75(10):1636-9. PubMed ID: 12777848
[TBL] [Abstract][Full Text] [Related]
19. Expression of B7 molecules in recipient, not donor, mice determines the survival of cardiac allografts.
Mandelbrot DA; Furukawa Y; McAdam AJ; Alexander SI; Libby P; Mitchell RN; Sharpe AH
J Immunol; 1999 Oct; 163(7):3753-7. PubMed ID: 10490971
[TBL] [Abstract][Full Text] [Related]
20. CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment.
Zheng XX; Markees TG; Hancock WW; Li Y; Greiner DL; Li XC; Mordes JP; Sayegh MH; Rossini AA; Strom TB
J Immunol; 1999 Apr; 162(8):4983-90. PubMed ID: 10202046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
